# LUX-Lung 4: BIBW 2992 (Afatinib) Phase I Trial in Advanced Non Small Cell Lung Cancer Patients & Phase II Trial in Non Small Cell Lung Cancer Patients Failing Erlotinib or Gefitinib

> **NCT00711594** · PHASE2 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 74 (actual)

## Conditions studied

- Carcinoma, Non-Small-Cell Lung

## Interventions

- **DRUG:** BIBW 2992 MA2 40mg/day
- **DRUG:** BIBW 2992 MA2 50mg/day
- **DRUG:** BIBW 2992 MA2 20mg/day
- **DRUG:** BIBW 2992 QD

## Key facts

- **NCT ID:** NCT00711594
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-04
- **Primary completion:** 2013-11
- **Final completion:** 2013-11
- **Target enrollment:** 74 (ACTUAL)
- **Last updated:** 2015-01-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00711594

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00711594, "LUX-Lung 4: BIBW 2992 (Afatinib) Phase I Trial in Advanced Non Small Cell Lung Cancer Patients & Phase II Trial in Non Small Cell Lung Cancer Patients Failing Erlotinib or Gefitinib". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT00711594. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*